100
Participants
Start Date
December 27, 2019
Primary Completion Date
March 9, 2021
Study Completion Date
March 9, 2021
Vortioxetine
Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
Marienthali Kliinik (EE0001), Tallinn
Tartu University Hospital (EE0002), Tartu
Cabinet du Docteur Patrick Bourgoin (FR0002), Angoulême
Cabinet Psyche (FR0004), Douai
Centre Medical Ambroise Pare (FR0003), Élancourt
Cabinet du Docteur Karim Boutayeb (FR0001), Viersat
Azienda Ospedaliera di Perugia - Policlinico Monteluce (IT0003), Perugia
Fondazione Santa Lucia IRCCS (IT0002), Rome
NZOZ Dom Sue Ryder - Pallmed Sp. z o.o. (PL0003), Bydgoszcz
CareClinic (PL0005), Katowice
Centrum Zdrowia Psychicznego Biomed - Jan Latala (PL0001), Kielce
Niepubliczny Zaklad Opieki Psychiatrycznej Mentis (PL0004), Leszno
Centrum Medyczne Luxmed Sp.Z O.O. (PL0006), Lublin
Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Sp.k. (PL0007), Poznan
Inje University Ilsan Paik Hospital (KR0002), Goyang-si
Chonnam National University Hospital (KR0003), Gwangju
Samsung Medical Center (KR0001), Seoul
Hospital Clinic de Barcelona (ES0003), Barcelona
Instituto Internacional de Neurociencias Aplicadas (ES0001), Barcelona
MlynowaMed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk (PL0009), Bialystok
Nzoz Syntonia (PL0010), Pruszcz Gdański
H. Lundbeck A/S
INDUSTRY